74 filings
Page 2 of 4
424B5
paxljdy3tycii
9 Mar 23
Prospectus supplement for primary offering
6:31am
8-K
8u96nhqq 31a4dwv
6 Jan 23
Results of Operations and Financial Condition
7:01am
8-K
zo2 vuqo2dptkq4ks2mt
31 Oct 22
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022
9:00am
8-K
9pi79dhq3 8ar27vxu
29 Sep 22
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
7:00am
8-K
niutwzus au
17 Jun 22
Submission of Matters to a Vote of Security Holders
7:00am
DEFA14A
0yv9ukl9rzuw0thu doz
28 Apr 22
Additional proxy soliciting materials
4:35pm
424B5
akr0evf
18 Feb 22
Prospectus supplement for primary offering
5:01pm
S-8
bg5aphoumqzcel
17 Feb 22
Registration of securities for employees
4:37pm
8-K
hhfz0lo rbr97kql3
9 Feb 22
Departure of Directors or Certain Officers
4:30pm
8-K
kd8m8f0c5 n6hpm5a8
27 Jan 22
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease
8:31am
8-K
ve5ofl res8t
5 Jan 22
Regulation FD Disclosure
4:02pm
EFFECT
izvgf
15 Nov 21
Notice of effectiveness
12:15am
UPLOAD
jp0d2ihc
10 Nov 21
Letter from SEC
12:00am
CORRESP
56fgj
10 Nov 21
Correspondence with SEC
12:00am